Pulmonary Arterial Hypertension

About

Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.

Articles

Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension

Citation:

US Cardiology 2006;3(1):1–5

Evaluation and Diagnosis of Pulmonary Arterial Hypertension

Citation:

US Cardiology 2006;3(1):30–2

The Role of Oral Vasoactive Agents in the Treatment of Pulmonary Arterial Hypertension

Citation:

US Cardiology 2006;3(1):39–42

Medical Treatment of Pulmonary Hypertension in 2004

Citation:

US Cardiology 2004;1(1):1-7